Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Medical genetics · Familial Hypobetalipoproteinemia Type 1

The Science of Your Diagnosis: Biology and Look-Alikes

At a Glance

FHBL1 is suspected when LDL cholesterol, total cholesterol, and ApoB are very low, but diagnosis usually requires genetic testing and family-history review. Testing helps distinguish APOB-related FHBL1 from abetalipoproteinemia and chylomicron retention disease.

Finding the cause of extremely low cholesterol requires a detective-like approach. Because several different genetic conditions can look nearly identical on a standard blood test, doctors must look deeper into your biology to confirm a diagnosis of Familial Hypobetalipoproteinemia Type 1 (FHBL1) [1][2]. Understanding the biological “glitch” behind the condition and how it differs from its “look-alikes” is the first step toward the right care plan.

The Biological “Glitch”: VLDL and Chylomicrons

To understand FHBL1, you have to look at how your body moves fat. Fats do not mix with water (or blood), so they must be packaged into spherical “shipping containers” called lipoproteins [3]. The APOB gene provides the instructions for the “frame” of these containers.

There are two main types of containers affected in FHBL1:

  • VLDL (Very Low-Density Lipoprotein): These are made in your liver (using the ApoB-100 protein) to ship energy out to the rest of your body [4].
  • Chylomicrons: These are made in your intestines (using the ApoB-48 protein) to transport absorbed dietary fats and vitamins into your bloodstream [5].

In FHBL1, the APOB variants create defective frames for these containers. Depending on the variant, these containers might be too small to carry much cargo, or they may be so broken that the liver and intestines cannot ship them out at all [3][4]. When these containers can’t leave, fats get “stuck” inside the liver cells (causing fatty liver) or the intestinal cells (causing digestive issues) [6][7].

The Diagnostic Roadmap

Doctors don’t use a single “magic number” to conclusively diagnose FHBL1. Instead, they look for clues and patterns in your profile.

1. Screening Clues

An important clue is having total cholesterol, LDL-C, and ApoB levels that fall below the 5th percentile for your age and sex [8][2]. An LDL-C below 50 mg/dL is often used as a practical trigger to start investigating [9]. However, these are screening clues, not absolute proof, and very low LDL can result from illness, medications, or other secondary causes.

2. Genetic Panels

Because the symptoms of FHBL1 can overlap with other conditions, doctors often use Next-Generation Sequencing (NGS) panels [10]. These panels test multiple genes at once—including APOB, MTTP, and SAR1B—to see exactly where the genetic error lies [10].

Differentiating the “Look-Alikes”

FHBL1 has two main look-alike conditions. Distinguishing between them is vital because they are inherited differently and may require different management.

Condition Gene Involved Inheritance Pattern Key Difference
FHBL1 APOB Codominant Often, at least one parent also has low cholesterol, though de novo variants can occur where neither parent is affected [1].
Abetalipoproteinemia (ABL) MTTP Recessive Parents usually have completely normal cholesterol levels [11].
Chylomicron Retention Disease (CMRD) SAR1B Recessive Primarily affects fat transport in the intestines; often presents with severe malnutrition in childhood [12][13].

The most important clue is often your family history. In FHBL1, because it is codominant, cascade testing of relatives can be helpful, although genetic counseling should be sought to fully understand the results [1][3].

Specialized Testing

If genetic testing is inconclusive, a specialist in a research or specialized metabolic setting might consider an oral fat-tolerance test. This test measures how your body responds to a high-fat meal by tracking ApoB-48 [14]. In FHBL1, there is often a small rise in ApoB-48 after the meal, whereas in Abetalipoproteinemia, it typically does not rise at all [4][14]. However, this is not a routine clinical test and requires specialized interpretation.

Getting a precise diagnosis is essential. It ensures that your care is focused on the right biological mechanism, whether that means protecting your liver from fat buildup or ensuring your body can absorb life-sustaining vitamins [9][15].

Common questions in this guide

How is familial hypobetalipoproteinemia type 1 diagnosed?
Doctors look for a pattern of very low LDL cholesterol, total cholesterol, and ApoB, often below the 5th percentile for age and sex. These results are screening clues rather than proof, so genetic testing, family history, and evaluation for other causes of low cholesterol may also be needed.
Which genes are tested when cholesterol is extremely low?
A next-generation sequencing panel may examine APOB, the gene associated with FHBL1, along with MTTP and SAR1B. Comparing these genes can help distinguish FHBL1 from abetalipoproteinemia and chylomicron retention disease.
How is FHBL1 different from abetalipoproteinemia?
FHBL1 is usually linked to an APOB variant and follows a codominant inheritance pattern, so one parent may also have low cholesterol. Abetalipoproteinemia is linked to MTTP and is recessive, so parents usually have normal cholesterol levels.
Can low cholesterol in a parent suggest FHBL1?
Yes. Because FHBL1 is usually codominant, an affected parent may also have unusually low cholesterol. Testing relatives can provide useful clues, but genetic counseling can help explain the results and their implications for the family.
What is chylomicron retention disease, and why can it look similar?
Chylomicron retention disease is a separate inherited condition caused by changes in SAR1B. It is recessive and mainly disrupts fat transport in the intestines, often causing severe malnutrition during childhood, which can help distinguish it from FHBL1.
What happens if genetic testing does not give a clear answer?
A specialist in a metabolic or research setting may consider an oral fat-tolerance test that measures ApoB-48 after a high-fat meal. A small ApoB-48 rise may occur in FHBL1, while little or no rise is more typical of abetalipoproteinemia, but this is not a routine test.

Get notified when new evidence is published on Familial hypobetalipoproteinemia 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1.

    Wakabayashi T, Takahashi M, Okazaki H, et al.

    Journal of atherosclerosis and thrombosis 2024; (31(7)):1005-1023 doi:10.5551/jat.RV22018.

    PMID: 38710625
  2. 2

    APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants.

    Vanhoye X, Janin A, Caillaud A, et al.

    International journal of molecular sciences 2022; (23(8)) doi:10.3390/ijms23084281.

    PMID: 35457099
  3. 3

    Homozygous familial hypobetalipoproteinemia: A Turkish case carrying a missense mutation in apolipoprotein B.

    Yilmaz BS, Mungan NO, Di Leo E, et al.

    Clinica chimica acta; international journal of clinical chemistry 2016; (452()):185-90.

    PMID: 26612772
  4. 4

    The Janus-faced manifestations of homozygous familial hypobetalipoproteinemia due to apolipoprotein B truncations.

    Di Leo E, Eminoglu T, Magnolo L, et al.

    Journal of clinical lipidology 2015; (9(3)):400-5.

    PMID: 26073401
  5. 5

    Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.

    Hooper AJ, Heeks L, Robertson K, et al.

    The Journal of clinical endocrinology and metabolism 2015; (100(11)):E1484-90 doi:10.1210/jc.2015-2731.

    PMID: 26323024
  6. 6

    Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease.

    Welty FK

    Current opinion in lipidology 2020; (31(2)):49-55 doi:10.1097/MOL.0000000000000663.

    PMID: 32039990
  7. 7

    Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia.

    Di Costanzo A, Di Leo E, Noto D, et al.

    Journal of clinical lipidology 2017; (11(5)):1234-1242 doi:10.1016/j.jacl.2017.06.013.

    PMID: 28733173
  8. 8

    Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature.

    Cefalù AB, Norata GD, Ghiglioni DG, et al.

    Atherosclerosis 2015; (239(1)):209-17.

    PMID: 25618028
  9. 9

    Clinical and biochemical spectrum of APOB-related hypobetalipoproteinemia: Insights from a retrospective cohort study.

    Sürücü Kara İ, Köse E, Mutlu H, et al.

    Journal of clinical lipidology 2025; (19(3)):605-616 doi:10.1016/j.jacl.2025.02.003.

    PMID: 40155282
  10. 10

    Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.

    Rimbert A, Pichelin M, Lecointe S, et al.

    Atherosclerosis 2016; (250()):52-6.

    PMID: 27179706
  11. 11

    Complex genetic architecture in severe hypobetalipoproteinemia.

    Wang LR, McIntyre AD, Hegele RA

    Lipids in health and disease 2018; (17(1)):48 doi:10.1186/s12944-018-0680-1.

    PMID: 29540175
  12. 12

    Novel mutations of SAR1B gene in four children with chylomicron retention disease.

    Simone ML, Rabacchi C, Kuloglu Z, et al.

    Journal of clinical lipidology 2019; (13(4)):554-562 doi:10.1016/j.jacl.2019.05.013.

    PMID: 31253576
  13. 13

    Update on the molecular biology of dyslipidemias.

    Ramasamy I

    Clinica chimica acta; international journal of clinical chemistry 2016; (454()):143-85.

    PMID: 26546829
  14. 14

    Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia.

    Kawashiri MA, Tada H, Hashimoto M, et al.

    JIMD reports 2015; (22()):85-94 doi:10.1007/8904_2015_415.

    PMID: 25763510
  15. 15

    Non-alcoholic fatty liver disease in a pediatric patient with heterozygous familial hypobetalipoproteinemia due to a novel APOB variant: a case report and systematic literature review.

    Molk N, Bitenc M, Urlep D, et al.

    Frontiers in medicine 2023; (10()):1106441 doi:10.3389/fmed.2023.1106441.

    PMID: 37384046

This page is for informational purposes only and does not constitute medical advice. Your clinician and genetic counselor should interpret your cholesterol results, genetic testing, and family history.